An important milestone in the treatment of glaucoma was the introduction of latanoprost with an entirely new mechanism of action compared to previously used antiglaucoma medications. Prostaglandin analogs (PGAs) have become the first-line treatment for primary open-angle glaucoma (POAG) primarily due to their efficacy, once-daily dosing, and minimal systemic side effects. The following recent review briefly summarizes the impact of the introduction of PGAs 25 years ago on current clinical practice in the treatment of glaucoma.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
